Compositions and methods for treating alzheimer's disease and parkinson's disease

a technology for parkinson's disease and alzheimer's disease, applied in the field of pharmaceutical compositions for treating alzheimer's disease and parkinson's disease, can solve the problems of inability to achieve the desired effect of clinical trials, interfere with a person's daily life and activities, and achieve the effects of reducing, preventing and/or eliminating one or more symptoms

Pending Publication Date: 2022-03-31
LA PHARMATECH INC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028]Aspect 12 is a method of treating a patient with Alzheimer's disease or Parkinson's disease, comprising administering to the patient an effective amount of a pharmaceutical composition comprising azelastine or a pharmaceutically acceptable salt

Problems solved by technology

Dementia is the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to such an extent that it interferes with a person's daily life and activities.
If untreated, AD ultimately leads to death.
So far, all promising approaches for decreasing Aβ or p-tau levels including mechanisms such as inhibition of Aβ o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

examples

[0060]A 70 year old patient with mid-stage Alzheimer's disease (AD) for 2 years and before treatment a baseline MMSE score of 12 and a Barthel Index (BI) of Activities of Daily Living score of 30, can be treated with a pharmaceutical composition of methylcobalamin and azelastine, e.g., a composition comprising methylcobalamin in an amount of 1.0 mg and azelastine, azelastine HCl or other salt thereof in an amount of 8 mg, up to twice daily (or any of the compositions described above or claimed, or for any treatment protocol or period of time described above or claimed). After 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, or more, one or more of his AD symptoms would be expected to improve by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or higher. For example, his MMSE score would be expected to improve from 12 to at least 22, which is an 83% improvement, and his BI score would be expected to improve from 30 to at least 80, which is a 167% improvement. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

Pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt of azelastine, and methylcobalamin are disclosed. Methods of using the pharmaceutical compositions for treating patients with Alzheimer's disease or Parkinson's disease are also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a Continuation application of U.S. patent application Ser. No. 16 / 913,927 filed Jun. 26, 2020, which published as U.S. Patent Application Publication No. 2020 / 0323873 on Oct. 15, 2020. The '927 application is a Continuation in Part application of U.S. patent application Ser. No. 16 / 382,885 filed on Apr. 12, 2019, which issued as U.S. Pat. No. 10,966,989 on Apr. 6, 2021, the disclosures of which are hereby incorporated by reference herein in their entireties.FIELD OF THE INVENTION[0002]The present invention relates to the field of practical medicine, namely, to the use of pharmaceutical compositions for treatment of Alzheimer's disease and Parkinson's disease. More specifically, the invention relates to novel combinations of compounds which can effectively treat Alzheimer's disease (AD) and Parkinson's disease (PD).BACKGROUND OF THE INVENTION[0003]Alzheimer's disease (AD) is a progressive, chronic neurodegenerati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/55A61K31/714
CPCA61K31/55A61K9/0053A61K31/714
Inventor WANG, JIANMINCUI, GEPING
Owner LA PHARMATECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap